
Benzinga Pro data, Mirati Therapeutics (NASDAQ:MRTX) reported Q4 sales of $299.00 thousand. Earnings fell to a loss of $199.62 million, resulting in a 149.36% decrease from last quarter. Mirati Therapeutics collected $71.79 million in revenue during Q3, but reported earnings showed a $80.05 million loss.